Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
Conclusion The combination therapy of apatinib plus S-1 was effective and well tolerated in the treatment of advanced ESCC patients after first-line chemotherapy failure. The combination therapy has the potential to be a potent therapeutic option for advanced ESCC patients after first-line chemotherapy failure.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | China Health | Drugs & Pharmacology | Esophagus Cancer | Hypertension | Investigational New Drugs | Oral Cancer | Proteinuria | Skin Cancer | Squamous Cell Carcinoma | Study